Final report of University Hospital Hradec Kralove to the clinical trial protocol no. GO28667

Abstract

A Multicenter, Phase III, Open-Label,Randomized Study in Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia To Evaluate The Benefit of GDC-0199 plus Rituximab compared with Bendamustime plus Rituximab

Keywords

• GDC-0199
• Rituximab
• Bendamustime